View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Suvoda WP
October 30, 2012updated 11 Jul 2022 9:58am

TauRx Therapeutics Alzheimer’s drug enters a two-phase third trial

Pharmaceutical company TauRx Therepeutics is starting to enroll Alzheimer's patients in its third-stage clinical trial for its experimental new drug LMTX.

By Heidi Vella

TauRx Therepeutics is starting to enroll Alzheimer's patients in a Phase III study of LMTX

Pharmaceutical company TauRx Therepeutics is starting to enroll Alzheimer’s patients in its third-stage clinical trial for its experimental new drug LMTX.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Yesterday afternoon the company announced it would be going ahead with vital third-stage trials needed for regulatory approval, saying it will test LMTX on 1,300 people in 21 different countries.

It will be a two-phase clinical trial, testing people with mild Alzheimer’s and people with mild-to-moderate Alzheimer’s, with the goal of halting the progression of the disease.

The drug at the centre of the trials, LMTX, works by targeting tangles of the Tau protein in the brain, dissolving them to prevent their harmful effects to memory.

Tau tangles were first discovered in the brain in the 1990s. TauRx Therapeutics Chairman Claude Wischik has been studying the tau approach ever since as professor of old age psychiatry at the University of Aberdeen in Scotland, where the company has its main research facilities.

Wischik said; "These Phase III studies are bringing us closer to finding an effective Alzheimer’s treatment that can actually arrest the progression of the disease. It really is time to test the role of tau."

LMTX has been created from altering an earlier product called Rember. Trials from 2008 showed that Rember produced a 90% reduction rate of disease progression over two years.

Companies currently investing in TauRx Therapeutics are Temasek Holdings, Singapore’s state-owned investment company, Development Bank of Singapore and Canada’s Dundee Corp.


Image: TauRx Therapeutics third stage trials are encouraging for Alzheimer’s suffers all over the world. Photo: Courtesy of Ben Earwicker.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology